Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12345678910111213...5960»
  • ||||||||||  Journal:  Remission of Acromegaly: The Sooner the Better. (Pubmed Central) -  Oct 7, 2024   
    While treatment strategies, biochemical cut-off to reach, and morbidities related to the persistence of the disease are well described in the literature, there is little data focusing on the delay to reach remission and its consequences. In this commentary, the authors discussed the results obtained from the UK acromegaly registry showing that the time to biochemical remission predicts the overall survival of patients in acromegaly.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Journal:  Difficulties of treating acromegaly in the light of 12 years of experience (Pubmed Central) -  Oct 6, 2024   
    In this commentary, the authors discussed the results obtained from the UK acromegaly registry showing that the time to biochemical remission predicts the overall survival of patients in acromegaly. No abstract available
  • ||||||||||  Biomarker, Journal:  Digital voice analysis as a biomarker of acromegaly. (Pubmed Central) -  Oct 4, 2024   
    Digital voice analysis can identify patients with acromegaly from short voice recordings with high accuracy. Patients with acromegaly experience more voice disorders than matched controls.
  • ||||||||||  Review, Journal:  Octreotide Causing Hyperkalemia: A Case Report and Review of the Literature. (Pubmed Central) -  Sep 30, 2024   
    Close monitoring of potassium levels and appropriate management strategies are essential to ensure the safe use of octreotide. This case aims to raise awareness and contribute to a better understanding of octreotide-induced hyperkalemia in CKD patients.
  • ||||||||||  Review, Journal:  Secondary diabetes mellitus in acromegaly: Case report and literature review. (Pubmed Central) -  Sep 27, 2024   
    This case emphasizes the need for comprehensive assessment in patients with acromegaly to address coexisting diabetic complications. Surgical and radiotherapeutic management of acromegaly can lead to significant metabolic improvements, highlighting the importance of interdisciplinary care in managing these complex cases.
  • ||||||||||  methimazole / Generic mfg.
    Journal:  Mixed thyrotropin-secreting pituitary neuroendocrine tumor coexisting with Graves' disease: a case report. (Pubmed Central) -  Sep 21, 2024   
    At 8 months after the surgery, the patient had a postoperative recurrence of hyperthyroidism, and methimazole (MMI) was then administered...When the circulating levels of both FT4 and FT3 were upregulated, non-suppressed TSH levels and positive thyroid antibodies were found. TSH PitNETs coexisting with GD should be carefully taken into account to avoid the potential risk of treatment-induced tumor progression.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati, Signifor LAR (pasireotide long acting release) / Recordati
    Retrospective data, Journal:  GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study. (Pubmed Central) -  Sep 20, 2024   
    Our data support a predictive role of the GHR isoforms for the occurrence of i-VFs in acromegalic patients treated with second-line drugs, tailored to the individual patient. The knowledge of the GHR polymorphism may facilitate the choice of second-line therapies, improving the therapeutic approach, in the context of personalized medicine.
  • ||||||||||  Review, Journal:  Medical treatment of acromegaly - When the tumor size matters: A narrative review. (Pubmed Central) -  Sep 15, 2024   
    Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).
  • ||||||||||  Journal:  ACROMORFO study: gait analysis in a cohort of acromegalic patients. (Pubmed Central) -  Sep 12, 2024   
    Disease control and remission appear to improve postural balance. A better knowledge on walking performance in acromegaly would help to develop specific rehabilitation programmes to reduce falls' risk and improve QoL.
  • ||||||||||  metformin / Generic mfg.
    Journal:  Activated AMP-protein kinase (pAMPK) is overexpressed in human somatotroph pituitary adenomas. (Pubmed Central) -  Sep 8, 2024   
    Contrary to earlier studies, conventional IHC markers such as Ki-67, SSTR2/5, and CAM5.2 were not useful for predicting biochemical remission at 3 months. Our data show, for the first time in human cells, an increase of cellular levels of pAMPK in sporadic somatotropinomas, regardless of cytokeratin pattern, as well as in GH-secreting adenomas from patients with germline AIP mutations.
  • ||||||||||  Journal:  Reassessment of Plurihormonal Pituitary Adenomas/PitNETs. (Pubmed Central) -  Sep 5, 2024   
    The extent of growth hormone, prolactin, thyroid stimulating hormone, PIT1, and SF1 IHC was variable, but immunopositivity for follicle-stimulating hormone and/or luteinizing hormone was nearly confined to co-expressors, distinguishing these from immature PIT1-lineage tumors. In conclusion, tumor size, invasiveness, and endocrinopathies do not distinguish PIT1/SF1 co-expressing tumors from immature PIT1-lineage tumors preoperatively; only full IHC pituitary workup allows distinction.
  • ||||||||||  Journal:  Incidence of bronchiectasis in patients with acromegaly: a cohort study. (Pubmed Central) -  Sep 2, 2024   
    In multivariable Cox proportional hazards regression modeling, the risk of bronchiectasis was significantly higher in patients with acromegaly than that in controls (HR: 1.49; 95% CI: 1.15-1.94, p = 0.0025) after adjusting for age, sex, household income, place, type 2 diabetes, hypertension, and dyslipidemia. Our results suggest that acromegaly may be associated with bronchiectasis.
  • ||||||||||  Review, Journal:  Unlocking the Genetic Secrets of Acromegaly: Exploring the Role of Genetics in a Rare Disorder. (Pubmed Central) -  Aug 28, 2024   
    Early detection and intervention are crucial for preventing complications and enhancing the quality of life for affected individuals. This review aims to elucidate the molecular, clinical, and histological characteristics of GH-secreting PitNETs, providing insights into their prevalence, treatment nuances, and the benefits of genetic testing for each type of genetic disorder associated with acromegaly.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. (clinicaltrials.gov) -  Aug 22, 2024   
    P=N/A,  N=100, Recruiting, 
    Preoperative low GH level and Knosp grades, including revised Knosp grades, are useful preoperative predictors for surgical remission of acromegaly. Trial completion date: Jul 2024 --> Apr 2026 | Initiation date: Sep 2023 --> Apr 2023 | Trial primary completion date: Jul 2024 --> Oct 2024
  • ||||||||||  Journal:  The comprehensive evaluation of oral and fecal microbiota in patients with acromegaly. (Pubmed Central) -  Aug 19, 2024   
    Trial completion date: Jul 2024 --> Apr 2026 | Initiation date: Sep 2023 --> Apr 2023 | Trial primary completion date: Jul 2024 --> Oct 2024 Patients with acromegaly show distinct gut microbiota profiles, and it is evident that factors beyond the GH/IGF-1 axis play a role in shaping the gut microbiota of individuals with acromegaly.
  • ||||||||||  Journal:  Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern. (Pubmed Central) -  Aug 14, 2024   
    SGST showed enrichment of neuronal development and acute inflammatory response pathways, along with a significant enhancement of JAK-STAT, phosphatidylinositol 3-kinase, and MAPK signaling. The results suggest that granulation-specific gene expression may underpin diverse clinical presentations in acromegaly, highlighting the potential for further investigation into these transcriptomic variations and their roles in disease pathology, particularly the involvement of genes linked to neuronal development, inflammatory response, and JAK-STAT signaling in SGST.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Journal:  Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. (Pubmed Central) -  Aug 12, 2024   
    Following a switch to pasireotide, the patient reported rapid and complete resolution of headaches and normalization of IGF-1 levels within a month of the treatment switch. This report underscores the challenges in acromegaly management and confirms the potential utility of pasireotide for patients suffering from treatment-resistant headache.
  • ||||||||||  Review, Journal:  New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases. (Pubmed Central) -  Aug 10, 2024   
    Lumbar BSI corrected for kyphosis could be proposed as integrated parameter of spine arthropathy and osteopathy in acromegaly helping the clinicians in identifying patients with skeletal fragility possibly predisposed to VFs. Assessing the status of the vitamin D/PTH axis and using vitamin D and PTH as therapeutic agents is mandatory in several endocrine-related bone metabolic conditions.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Review, Journal:  A Review on Coexisting Giants: The Interplay Between Acromegaly and Diabetes Mellitus. (Pubmed Central) -  Aug 9, 2024   
    This review article has compiled studies to demonstrate a link between acromegaly. It summarises the existing data on acromegaly associated with DM, explicitly understanding the effect of various medical treatments on glucose homeostasis.
  • ||||||||||  Journal:  Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR). (Pubmed Central) -  Aug 8, 2024   
    For Knosp grade 1-3 functional pituitary neuroendocrine tumor surgery, if there is no clear false envelope or normal pituitary between the tumor and the cavernous sinus medial wall during the operation, the cavernous sinus medial wall should be actively removed to improve the postoperative endocrine remission rate. In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.